Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series F brings in $30mm for Glaukos

Executive Summary

Meritech Capital Partners has led ophthalmic device firm Glaukos Corp.’s $30mm Series F venture round. Existing backers including Versant Ventures, Domain Associates, Montreux Equity Partners, InterWest Partners, Frazier Healthcare, OrbiMed Advisors, and Gund Investment Corp. also participated. Glaukos will use the money to fund the US commercial launch of its iStent trabecular micro-bypass device, which was approved in June 2012 for use during micro-invasive glaucoma surgery, as well as for pivotal registration studies of the next-generation inject and iStent supra suprachoroidal implant.
Deal Industry
  • Medical Devices
  • Medical Devices
    • Implantable Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies